The lysosomotropic amines, chloroquine and hydroxychloroquine: A potentially novel therapy for graft-versus-host disease

Leukemia and Lymphoma

Volumn 24, Issue 3-4, 1997, Pages 201-210

  Schultz, Kirk R ^a   Gilman, Andrew L ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antigen presentation; Chloroquine; Graft versus host disease; Hydroxychloroquine; Lysosomotropic amines

Indexed keywords

AMINE; CHLOROQUINE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0031054565     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039008     Document Type: Review

References (59)

1. Ferrara, J. and Burakoff, S. (1990) The pathophysiology of acute graft-versus-host disease in a murine bone marrow transplant model. In Burakoff, S., Deeg, H. J., Ferrara, J. and Atkinson K. (Eds): Graft-versus-Host Disease: Immunology, Pathophysiology, and Treatment, (p. 9). New York, NY, Dekker.
2. Vogelsang, G. B. and Hess, A. D. (1994) Graft-versus-host disease: New directions, for a persistent problem. Blood, 84, 2061-2067.
3. Dietrich, P. Y , Caignard, A., Lim, A., Chung, V., Pico, J. L., Pannetier, C., Kourilsky, P., Hercend, T., Even, J. and Treibel, F. (1994) In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood, 84, 2815-2820.
4. Korngold, R. and Wettstein, P. J. (1990) Immunodominance in the graft-versus-host response to minor histocompatibility antigens. J. Immunol., 145, 4079-88.
5. Wettstein, P. J. and Korngold, R. (1987) Immunodominance in the T cell responses to multiple non H-2 histocompatibility antigens. IV. Partial tissue distribution and mapping of immunodominant antigens. J. Immunol., 139, 2166-2171.
6. Korngold, R. (1991) Pathophysiology of graft-versus-host disease directed to minor histocompatibility antigens. BMT, 7, Suppl 1, 38-41.
7. Hamilton, B. L. and Parkman, R. (1983) Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation, 36, 150-155.
8. Truitt, R. L. and Atasoylu, A. A. (1991) Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus- leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplantation, 8, 51-58.
9. van Els, C. A. C. M., Bakker, A., Zwinderman, A. H., Zwaan, F. E , van Rood, J. J. and Goulmy, E. (1990) Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II Evidence of a possible involvement of proliferative T cells. Transplantation, 50, 67-71.
10. Bunjes, D., Theobald, M., Nierle, T , Arnold, R. and Heimpel, H (1995) Presence of host-specific interleukin-2 T helper cell precursors correlates closely with active primary and secondary chronic graft-versus-host disease. BMT, 15, 727-32.
11. Niederweiser, D., Grassegger, A., Auböck, J., Herold, M., Nachbaur, D., Rosenmayr, A., Gächter, A., Nussbaumer, W., Gaggi, S., Ritter, M. and Huber, C. (1993) Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood, 81, 2200-8.
12. Metlay, J. P., Pure, E. and Steinman, R. M. (1989) Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Advances in Immunology, 47, 45-116.
13. Guman, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J. and Nadler, L. M. (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84, 3261-3282.
14. Sinigaglia, F and Hammer, J. (1994) Defining rules for the peptide-MHC class II interaction. Current Opinion Immunol., 6, 52-56
15. Sant, A J. and Miller, J. (1994) MHC class II antigen processing: biology of invariant chain. Current Opinion Immunol., 6, 57-63.
16. Loss, G. E., Elias, C. G., Fields, P. E., Ribaudo, R. K., McKisic, M. and Sant, A. J. (1993) Major histocompatibility complex class II-restricted presentation of an internally synthesized anti gen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathway. J. Exp. Med., 178, 73-85.
17. Loss, G. E. and Sant, A. J. (1993) Invariant chain retains MHC class II molecules in the endocytic pathway. J. Immunol., 150, 3187-3187.
18. Schultz, K. R., Paquet, J., Abbott, G., Bader, S. and HayGlass, K. T. (1995) Requirement For B Cells in T cell priming to minor histocompatibility antigens and induction of graft-versus-host disease. BMT, 16, 289-95.
19. Bader, S , Bugar, J. and Schultz, K. R. Effect of donor dendritic cell depletion on graft-versus-host disease secondary to minor histocompatibility (MiHC) antigen differences. J. Hematotherapy 4:208, 1995 (Abstract)
20. Krenger, W., Snyder, K., Smith, S. and Ferrara, J. L. (1994) Effects of exogenous interleukin-10 in a murine model of graft- versus-host disease to minor histocompatibility antigens. Transplantation, 58, 1251-7.
21. Blazar, B. R., Taylor, P. A , Smith, S. and Valler, D. A. (1995) lnterleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood, 85, 842-51.
22. Schlegel, P. G., Aharoni, R., Smilek, D. E., Fernandez, L. P., McDevitt, H. O., Tran, N., Vaysburd, M. and Chao, N. J. (1994) Prevention of Graft-versus-Host Disease by peptides binding to class II major histocompatibility complex molecules Blood, 84, 2802-2810.
23. Schlegel, P. G., Vaysburd, M., Chen, V , Butcher, E. C. and Chao, N. J. (1995) Inhibition of T cell costimulation by VCAM- 1 prevents murine graft-versus-host disease across minor histocompatibility antigens. J. Immunology, 155, 3856-65.
24. Van Gool, S. W., de Boer, M. and Ceuppens, J. L. (1994) The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J. Exp. Med., 179, 715-201.
25. Lombard-Platlet, S., Bertolino, P., Deng, H., Gerlier, D. and Rabourdin-Combe, C. (1993) Inhibition by chloroquine of the class II histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding cell. Immunology, 80, 566-573.
26. Humbert, M., Raposo, G., Cosson, P., Reggio, H , Davoust, J. and Salamero, J. (1993) The invariant chain induces compact forms of class II molecules localized in late endosomal compartments. Eur J. Immunol., 23, 3158-66.
27. Mizuochi, T., Yee, S. T., Kasai, M., Kakiuchi, T., Muno, D. and Kominami, E. (1994) Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. Immunology Letters, 43, 189-93.
28. Maric, M. A., Taylor, M. D. and Blum, J. S. (1994) Endosomal aspartic proteinases are required for invariant-chain processing. Proc. Natl. Acad. Sci. USA, 91, 2171-2175.
29. Carrasco-Marin, E., Alvarez, D. C. and Leyva, C. F. (1994) Wortmannin, in inhibitor of phospholipase D activation, selectively block major histocompatibility complex class II- restricted antigen presentation. Eur. J. Immunol., 24, 2031-39.
30. Kleijmeer, M. J., Ossevoort, M A. and van, V. C. et, al. (1995) MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells J. Immunol., 154, 5715-24.
31. Koch, N., Moldenhauer, G., Hofmann, W. J. and Moller, P. (1991) Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J. Immunol., 147, 2643-2651.
32. Sperber, K., Quaraishi, H., Kalb, T. H., Panja, A., Stecher, V. and Mayer, L. (1993) Selective regulation of cytokine secretion by chloroquine- Inhibition of IL-1 and IL-6 by monocytes and T cells. J. Rheumatol., 20, 803.
33. Ngheim, L. N., Banfalvi, G., Csuka, I., Olah, I. and Antoni, F. (1987) In vitro effect of emetine and chloroquine on the macro- molecular biosynthesis of murine thymus cells. Acta Biochim. et Biophys. Hungarica, 22, 75-83.
34. Schultz, K. R., Nelson, D. and Bader, S. Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. Bone Marrow Transplantation (In press).
35. Wallace, D J. (1994) Antimalarial agents and lupus. Rheum. Dis. Clin. North Amer., 20, 243-263.
36. Fox, R. I. (1993) Mechanism of action of hydroxychloroquine as an anti-rheumatic drug. Semin. Arthritis Rheum , 23, 82-91.
37. Reid, P. A. and Watts, C. (1990) Cycling of cell surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature, 346, 655-657.
38. Gilman, A. L., Beams, F., Tefft, M. and Mazumder, A. (In press) The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplantation.
39. Schultz, K R. and Bader, S. (1995) Effect of chloroquine on cytolytic T-cell priming to minor histocompatibility antigens, graft-versus-host disease and T-cell leukemia-vaccine responses. Med. Ped. Onc., 25, 285
40. Roder, J. C., Argov, S., Klein, M., Petersson, C , Kiessling, R., Andersson, K. and Hansson, M. (1983) target-effector cell interaction in the natural killer cell system: V. Energy requirements, membrane integrity, and the possible role of lysosomal enzymes. Immunology, 40, 107-116
41. Schultz, K. R., Bader, S., Paquet, J. and Li, W. (1995) Chloroquine treatment affects T cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood, 86, 4344-52
42. Ertel, W., Morrison, M H., Ayala, A and Chaudry, I. H. (1991) Chloroquine attenuates hemorrhagic shock-induced suppression of kupffer cell antigen presentation and major histocompatibility complex class II antigen presentation through blockade of tumor necrosis factor and prostaglandin release. Blood, 78, 1781-188.
43. Nelson, D., Bader, S and Schultz, K. R. (1995) Synergy of chloroquine and cyclosporin A in vitro on T cell responses to minor histocompatibility antigen and tetanus toxoid. Blood, 86 (Supp 1), 224a.
44. Lam, G. K. Y. (1993) The differential aspects of the linear isobole in the study of combined action of agents. Bull. Mathematical Biol., 55, 295-313.
45. McChesney, E. W. (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med., 75, 11-18.
46. Tett, S. E., Cutler, D. J. and Brown, C. F. (1985) A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. J. Chromatography, 344, 241-248.
47. MacKenzie, A. H. (1983) Pharmacologic actions of 4-aminoquinoline compounds. Am. J. Med., 75, 5-10.
48. Miller, D. R., Fiechtner, J. J., Carpenter, J. R., Brown, R. R., Stroshane, R. M. and Stecher, V. J. (1987) Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthr. Rheum., 30, 567-571.
49. Cutler, D., MacIntyre, A. and Tett, S. (1988) Pharmacokinetics of 4-Aminoquinoline antimalarials. AAS, 24, 142-157.
50. Kersley, G. D. (1959) Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet, 886-888.
51. Avital, A., Godfrey, S., Maayan, Ch., Diamant, Y. and Springer, C. (1994) Chloroquine treatment of interstitial lung disease in children. Pediatr. Pulm., 18, 356-360.
52. Mainland, D. and Sutcliffe, M. (1962) Hydroxychloroquine sulfate in rheumatoid arthritis, a six month, double-blind trial. Bulletin of the Rheumatic Diseases, 13, 3897-290.
53. Wallace, D. J. (1994) Antimalarial agents and lupus. Rheum. Dis. Clin. North Amer., 20, 243.
54. LaSalle, J. M. and Hafler, D. A. (1994) T cell anergy. FASEB J., 8, 601-8.
55. Lanzevecchia, A. (1993) Identifying strategies for immune intervention. Science, 260, 937-44.
56. Pichler, W. J. and Wyss-Coray. (1994) T cells as antigen-presenting cells. Immunol. Today, 15, 312-5.
57. Ho, W. Y., Cooke, M. P., Goodnow, C. C. and Davis, M. M. (1994) Resting and anergic B cells are defective in CD28- dependent costimulation of naive CD4+ T cells. J. Exp. Med., 179, 1539-49.
58. Fowler, D. H., Kurasawa, K., Smith, R., Eckhaus, M. A. and Gress, R. E. (1994) Donor CD4-enriched cells of the Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood, 84, 3540-3549.
59. Mamula, M. J and Craft, J. (1994) The expression of self determinants: implications for tolerance and autoimmunity. Current Opinion Immunology, 6, 882-6.